Who manufactures BioThrax?
Who manufactures BioThrax?
Emergent BioSolutions Inc.
About Emergent BioSolutions Inc. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax.
Who owns Emergent BioSolutions Inc?
Fuad El-Hibri
Emergent BioSolutions
| Type | Public company |
|---|---|
| Founder | Fuad El-Hibri |
| Headquarters | Gaithersburg, Maryland, U.S. |
| Key people | Robert G. Kramer Sr. (CEO) Fuad El-Hibri (Executive Chairman of the Board of Directors) |
| Revenue | US$1.11 billion (2019) |
Who is the CEO of Emergent BioSolutions?
Robert G. Kramer Sr. (Apr 1, 2019–)
Emergent BioSolutions/CEO
The next phase of the investigation will see Emergent founder and executive chairman Fuad El-Hibri and CEO Robert Kramer testify before the House Select Subcommittee on the Coronavirus, the committee announced Wednesday.
How many people work at Emergent BioSolutions?
Emergent (NYSE:EBS), which is headquartered in Gaithersburg, has 1,300 employees working across 13 locations, including multiple facilities in Baltimore. The company had a revenue of $782 million in 2018, up from about $561 million the prior year, according to filings with the U.S. Securities and Exchange Commission.
How much does BioThrax cost?
FORMS
| brand name | preparation | cost* |
|---|---|---|
| BioThrax | Anthrax Vaccine Adsorbed | $900 per vial |
When was BioThrax FDA approved?
In December 2008, the FDA approved the new BioThrax IM formulation for intramuscular injections thus reducing the immunization schedule from a total of 6 shots to 5 shots (see below).
What kind of company is emergent BioSolutions?
global specialty biopharmaceutical company
Emergent BioSolutions Inc. operates as a global specialty biopharmaceutical company. The Company develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.
What type of company is emergent BioSolutions?
global life sciences company
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats.
What is an emergent situation?
Unforeseen emergent situation means an unusual, unpredictable or unforeseen circumstance such as, but not limited to, an act of terrorism, a disease outbreak, adverse weather conditions or natural disasters.
Who are Emergent BioSolutions competitors?
The top 10 competitors in Emergent BioSolutions’ competitive set are Novavax, Moderna, Inovio, GeoVax, XBiotech, Zymeworks, Arrowhead, Dynavax, Immune Design, Brickell Biotech. Together they have raised over 15.3B between their estimated 210.2K employees.
When was Emergent BioSolutions founded?
September 5, 1998
Emergent BioSolutions/Founded
What type of vaccination is anthrax?
The only licensed anthrax vaccine, Anthrax Vaccine Adsorbed (AVA) or BioThraxTM is indicated for active immunization for the prevention of disease caused by Bacillus anthracis, in persons 18 – 65 years of age at high risk of exposure.